Antibiotic
For the treatment of bovine respiratory disease (BRD) associated with Pasteurella multocida, Mannheimia haemolytica, Histophilus somni and Mycoplasma bovis.
One shot, two active molecules
Enrofloxacin, the active ingredient in Tenotryl™ is an efficient, broad-spectrum antibiotic that has been trusted in the U.S. cattle industry for 25 years. Once injected into cattle, enrofloxacin is metabolized into enrofloxacin and ciprofloxacin.1 These molecules deliver different modes of action for optimal efficacy. Therefore it delivers prompt, combined strengths against the primary pathogens that cause bovine respiratory disease (BRD).
Tenotryl™ works quickly at the infection site with enrofloxacin reaching peak plasma concentration in less than two hours.1 It remains active because ciprofloxacin has a maximum residence time of 13.7 hours.1
Designed to be fast and reliable
A single injection of enrofloxacin has a relatively brief period of effect. After a single subcutaneous injection of 12.5 mg/kg, the combined, unbound concentrations of enrofloxacin and ciprofloxacin are below the minimal inhibitory count (MIC) for 90% of Mannheimia haemolytica isolates in plasma and tissue fluids by 48 hours.2 Do not exceed a 20 mL dose per injection site. Subcutaneous injection in cattle can cause a transient local tissue reaction and may result in trim loss of edible tissue at slaughter.
Designed to deliver broad spectrum efficacy
Enrofloxacin is a broad-spectrum antibiotic with low minimal inhibitory concentration on the primary agents of bovine respiratory disease. Its bactericidal effects are concentration and time dependent.3
Indications:
Single-Dose Therapy: Tenotryl™ is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis in beef and non-lactating dairy cattle; and for the control of BRD in beef and non-lactating dairy cattle at high risk of developing BRD associated with M. haemolytica, P. multocida, H. somni and M. bovis.
Multiple-Day Therapy: Tenotryl™ is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni in beef and non-lactating dairy cattle.
SWINE IMPORTANT SAFETY INFORMATION
Tenotryl™ (enrofloxacin) 100 mg/ml Antimicrobial Injectable Solution: Not for use in humans. For subcutaneous use in beef cattle and non-lactating dairy cattle. Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal. Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian and prohibits the extra-label use of this drug in food producing animals. Animals intended for human consumption must not be slaughtered within 28 days from the last treatment. This product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in the calves born to these cows. A withdrawal period has not been established for this product in pre-ruminating calves. The effects of enrofloxicin on cattle reproductive performance, pregnancy and lactation have not been adequately determined. Do not exceed a 20 mL dose per injection site. Subcutaneous injection in cattle can cause a transient local tissue reaction and may result in trim loss of edible tissue at slaughter. Quinolone-class drugs should be used with caution in animals with known or suspected Central Nervous System (CNS) disorders.
References
- McKellar, Q., Gibson, I., Monteiro, A., Bregante, M. 1999. Pharmacokinetics of Enrofloxacin and Danofloxacin in Plasma, Inflammatory Exudate, and Bronchial Secretions of Calves following Subcutaneous Administration. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1999, p. 1988–1992.
- Apley, Michael D., DVM, Ph.D. 2015. Treatment of Calves with Bovine Respiratory Disease; Duration of Therapy and Posttreatment Intervals - Vet Clin Food Anim 31 (2015) 441–453.
- Giguére, S.; Prescot, J.F.; Dowling, P.M. 2013. Antimicrobial Therapy in Veterinary Medicine, Fifth Edition.
- Stanford, et al. Antimicrobial Resistance in Members of the Bacterial Bovine Respiratory Disease Complex Isolated from Lung Tissue of Cattle Mortalities Managed with or without the Use of Antimicrobials. Microorganisms 2020, 8, 288.
- Portis, et al. A ten-year (2000–2009) study of antimicrobial susceptibility of bacteria that cause bovine respiratory disease complex—Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni—in the United States and Canada. Journal of Veterinary Diagnostic Investigation 24(5) 932–944.